Foresite Capital Management Ii, LLC Adaptimmune Therapeutics PLC Transaction History

Foresite Capital Management Ii, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$3.63 - $6.06 $2.54 Million - $4.24 Million	-700,000 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$3.76 - $14.16 $752,000 - $2.83 Million	200,000 Added 40.0%	700,000 $4.03 Million
Q3 2018 Nov 13, 2018	SELL	$8.27 - $13.56 $1.65 Million - $2.71 Million	-200,000 Reduced 28.57%	500,000 $6.78 Million
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $3.13 Million - $4.12 Million	300,000 Added 75.0%	700,000 $8.31 Million
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $2.84 Million - $4.62 Million	400,000 New	400,000 $4.49 Million

160M

42.8K

42.1K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $199M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Ii, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Ii, LLC with notifications on news.